|
|
|
|
| LEADER |
02558nmm a2200433 u 4500 |
| 001 |
EB002136200 |
| 003 |
EBX01000000000000001274327 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
221205 ||| eng |
| 100 |
1 |
|
|a Klatzmann, David
|
| 245 |
0 |
0 |
|a Treating autoimmune and inflammatory diseases with enhanced regulatory T-cells
|h Elektronische Ressource
|c David Klatzmann
|
| 260 |
|
|
|a London
|b Henry Stewart Talks
|c 2022, 2022
|
| 300 |
|
|
|a 1 streaming video file (54 min.)
|b color, sound
|
| 653 |
|
|
|a Liver
|
| 653 |
|
|
|a Interleukin-2 / therapeutic use
|
| 653 |
|
|
|a Autoimmune Diseases / drug therapy
|
| 653 |
|
|
|a Lung
|
| 653 |
|
|
|a Graft vs Host Disease / immunology
|
| 653 |
|
|
|a Inflammation / Treatment
|
| 653 |
|
|
|a Immunotherapy / methods
|
| 653 |
|
|
|a T cells / Therapeutic use
|
| 653 |
|
|
|a Interleukin-2 / Therapeutic use
|
| 653 |
|
|
|a Infections / immunology
|
| 653 |
|
|
|a Cell- and Tissue-Based Therapy
|
| 653 |
|
|
|a T-Lymphocytes, Regulatory / therapeutic use
|
| 653 |
|
|
|a Spleen
|
| 653 |
|
|
|a CTLA-4 Antigen
|
| 653 |
|
|
|a Autoimmune Diseases / Immunology
|
| 653 |
|
|
|a Adoptive Transfer
|
| 653 |
|
|
|a Forkhead Transcription Factors
|
| 653 |
|
|
|a Autoimmune diseases / Treatment
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b HST
|a Henry Stewart Talks
|
| 490 |
0 |
|
|a The biomedical & life sciences collection
|
| 500 |
|
|
|a Title from title frames. - Webinar. - Mode of access: World Wide Web
|
| 856 |
4 |
0 |
|u https://hstalks.com/bs/5115
|x Verlag
|z Streaming video file
|
| 082 |
0 |
|
|a 570
|
| 520 |
|
|
|a Interleukin-2 (IL-2) is the main cytokine supporting regulatory T-cells (Tregs) development, survival and suppressive activity. However, Tregs cannot produce IL-2 and fully depend on exogenous IL-2. Treg cell therapy products are grown for weeks in culture medium containing IL-2 concentration that are 10 000-fold higher than the IL-2 serum concentration in humans. This generates "IL-2 addicted" Tregs that might not survive well and/or function optimally when reinjected in patients. We reasoned that Tregs that could produce their own IL-2 would have markedly improved therapeutic potential. ... Altogether, we believe that Treg cell products should be supported by IL-2 after injection to patients. This could be done by injecting low-dose IL-2 or advantageously by an autocrine production of IL-2 that dramatically improves the therapeutic potential of Tregs. This approach could be introduced in any form of Treg cell therapy, from polyclonal Tregs to antigen specific or targeted Tregs
|